Jain PharmaBiotech

Basel, Switzerland

Jain PharmaBiotech

Basel, Switzerland

Time filter

Source Type

DUBLIN, May. 10, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering. The markets for RNAi are difficult to define as no RNAi-based product is approved yet but...


DUBLIN, May 11, 2017 /PRNewswire/ -- Dublin - Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering. This report deals with cytogenetics in a broader sense rather than the...


DUBLIN, May 10, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Nanobiotechnology Applications, Markets and Companies" to their offering. An increasing use of nanobiotechnology by the pharmaceutical and biotechnology...


DUBLIN, May. 08, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays - Technologies, Markets and Companies" to their offering. This report is an analysis of biochip/microarray markets based on...


DUBLIN, May 10, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Transdermal Drug Delivery - Technologies, Markets, and Companies" to their offering. This report deals with transdermal drug delivery - an approach used to...


DUBLIN, May. 10, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering. Gene therapy can now combine with antisense techniques such as RNA interference...


DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering. This report deals with therapeutic drug monitoring, a multi-disciplinary...


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering. Gene therapy can now combine with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression. Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included. The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2016-2026. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets Profiles of 187 companies involved in developing gene therapy are presented along with 232 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. For more information about this report visit http://www.researchandmarkets.com/research/nlrnwm/gene_therapy


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering. The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2016 to 2026. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc. Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids. Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending. Profiles of 162 companies involved in developing RNAi technologies are presented along with 230 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 36 are involved in microRNAs. The bibliography contains selected 650 publications that are cited in the report. The text is supplemented with 38 tables and 15 figures. For more information about this report visit http://www.researchandmarkets.com/research/5nz4nw/rnai


Jain K.K.,Jain PharmaBiotech
BMC Medicine | Year: 2010

Nanooncology,the application of nanobiotechnology to the management of cancer,is currently the most important chapter of nanomedicine.Nanobiotechnology has refined and extended the limits of molecular diagnosis of cancer,for example,through the use of gold nanoparticles and quantum dots. Nanobiotechnology has also improved the discovery of cancer biomarkers,one such example being the sensitive detection of multiple protein biomarkers by nanobiosensors.Magnetic nanoparticles can capture circulating tumor cells in the bloodstream followed by rapid photoacoustic detection. Nanoparticles enable targeted drug delivery in cancer that increases efficacy and decreases adverse effects through reducing the dosage of anticancer drugs administered. Nanoparticulate anticancer drugs can cross some of the biological barriers and achieve therapeutic concentrations in tumor and spare the surrounding normal tissues from toxic effects. Nanoparticle constructs facilitate the delivery of various forms of energy for noninvasive thermal destruction of surgically inaccessible malignant tumors.Nanoparticle-based optical imaging of tumors as well as contrast agents to enhance detection of tumors by magnetic resonance imaging can be combined with delivery of therapeutic agents for cancer.Monoclonal antibody nanoparticle complexes are under investigation for diagnosis as well as targeted delivery of cancer therapy.Nanoparticle-based chemotherapeutic agents are already on the market,and several are in clinical trials. Personalization of cancer therapies is based on a better understanding of the disease at the molecular level,which is facilitated by nanobiotechnology.Nanobiotechnology will facilitate the combination of diagnostics with therapeutics, which is an important feature of a personalized medicine approach to cancer. © 2010 Jain; licensee BioMed Central Ltd.

Loading Jain PharmaBiotech collaborators
Loading Jain PharmaBiotech collaborators